Supramaximal dose of candesartan in proteinuric renal disease - Wikidata - awgldk - TriplyDB

Supramaximal dose of candesartan in proteinuric renal disease

Supramaximal dose of candesartan in proteinuric renal disease

http://www.wikidata.org/entity/Q24649685

about

Reducing cardiorenal risk through combination therapy with a direct renin inhibitor Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Monitoring kidney function and albuminuria in patients with diabetes.Comparing angiotensin II receptor blockers on benefits beyond blood pressure Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility World kidney day 2011: protect your kidneys, save your heart.Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.Cardio classics revisited--focus on the role of candesartan.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).Nuclear expression of renin-angiotensin system components in NRK-52E renal epithelial cells.World Kidney Day 2011 - Protect your kidneys, save your heart.The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease Retarding the progression of chronic kidney disease with renin angiotensin system blockade The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers Sexual dimorphism in urinary angiotensinogen excretion during chronic angiotensin II-salt hypertension.Inhibition of renin activity slows down the progression of HIV-associated nephropathy Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.Candesartan: widening indications for this angiotensin II receptor blocker?Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Losartan chemistry and its effects via AT1 mechanisms in the kidney Application of direct renin inhibition to chronic kidney disease.Which antihypertensive drugs are the most nephroprotective and why?Managing kidney disease with blood-pressure control.Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives.Improving the efficacy of RAAS blockade in patients with chronic kidney disease.Treatment strategies to prevent renal damage in hypertensive children.Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy.Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.The appropriate dose of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD.Achieving remission of proteinuria in childhood CKD.Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.

P2860

Q26851307-FB06180F-203F-40E0-8570-704C2F3681EE Q26865691-9F974285-DCE4-414F-9DC4-9D627E3B7AF7 Q27007027-A763D412-FC8C-4B9C-98F9-A6603B7FDB99 Q27691297-0ECB2E5F-4330-4A8F-91E5-909E4718BAC0 Q30360678-C4DE680B-704C-4A0F-8D1A-6A822E6DD0DE Q33571219-1B32EBD0-C2A0-475E-8196-FA39F18EC1E9 Q33871733-41E6CB59-D925-465D-8065-EFE71B0A4162 Q34390088-08228B9D-9901-42DA-B597-1BF10EEFE961 Q34417462-3317CA6F-14EB-4B00-B1DB-65CA303CF0B6 Q34604473-BFE8EC4B-6449-4C5A-81B5-E2B787C48A00 Q34627724-747DD15B-C775-487C-AEE8-F3AFF4AFA66A Q34772555-311AA5CA-7E96-4954-BC73-EFA4EA1089FE Q35673984-4655C873-FE54-4F42-AA83-0C6349337619 Q35914820-49DD69EE-B01A-45EB-AE5D-03209FEDCFDC Q36082302-A1442333-8A68-42B3-B156-6B0F3E6A004D Q36125465-F664D6BD-7FD4-4929-BAD6-0C4740A87FB5 Q36166426-4B4229DD-393A-4E1B-BFC0-71E780A841F4 Q36309378-DBA070FF-2702-433B-AF57-64C78F700D85 Q36329456-C70A6C32-703A-42BC-9274-05B8A8C727C6 Q36410269-C29F29D3-F46E-414D-B4CE-3E611997E8F1 Q36701736-DE9B4221-4E6E-4DCA-B42D-24A9AF8EE5B0 Q37534746-DC703983-77FD-4EF8-9269-B7E8DA37C2CF Q37574913-87BBECE7-631B-4F8C-A607-A5F57841BEC7 Q37595616-1C8CE94A-78F3-4536-8E99-E2BF298F6C55 Q37758534-3E221FD6-E4EA-4945-93B4-0071D811C2AF Q37803235-83C5E3E9-0081-4190-B662-FF2EFCC5AD55 Q37892340-F030C933-6515-4F7A-A7C4-686CA1EE141C Q37959062-3FE430AA-112B-488D-9847-D4F5A3869058 Q38068099-90C3F210-E6B2-4E4B-9952-8E38BA533A16 Q38187597-52C2DFB8-E261-4EDC-89F3-F7123E4C1214 Q38399141-2E3C8143-18A8-4F88-95E0-24A1DE69E065 Q38777543-21D30D1A-030F-408C-93DD-AC91A4A865C9 Q38845433-1DD3B337-FDFF-4C48-AE86-CEF7B134DA1A Q39893116-85A87E17-A5FD-4411-8732-D38727523AB5 Q41652967-EA251BC2-3143-4417-86EA-9D1B8903DA5C Q42383448-927059E3-108F-4A6A-B125-8D10EB16407E Q42499130-BD147844-18A2-4A47-85DC-CF6716B2674E Q48320229-8BE1BC82-DD2C-479E-BB61-89C58E28A8E6 Q50095858-E0C11C47-4406-4058-A6A0-844E538A5127 Q50730577-1EC413FD-283A-4BD6-8E11-4747F0DF24D8

P2860

Supramaximal dose of candesartan in proteinuric renal disease

http://www.wikidata.org/entity/Q24649685

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Supramaximal dose of candesartan in proteinuric renal disease

@ast

Supramaximal dose of candesartan in proteinuric renal disease

@en

Supramaximal dose of candesartan in proteinuric renal disease

@nl

type

label

Supramaximal dose of candesartan in proteinuric renal disease

@ast

Supramaximal dose of candesartan in proteinuric renal disease

@en

Supramaximal dose of candesartan in proteinuric renal disease

@nl

prefLabel

Supramaximal dose of candesartan in proteinuric renal disease

@ast

Supramaximal dose of candesartan in proteinuric renal disease

@en

Supramaximal dose of candesartan in proteinuric renal disease

@nl

P1433

Q24649685-00C00A57-B54C-4A3E-A5DC-42AE0ECF5871

P1476

Q24649685-6AC40E18-ABA3-4869-A05A-EB67FD6C1645

P2093

Q24649685-0D21ADE2-2475-43AE-86AE-26D2BAD6467A

Q24649685-52E46157-D55C-4C12-A017-87CD0568BB10

Q24649685-5AE5390D-C060-424C-A225-9A3233E1FDBF

Q24649685-93B6CF16-9E5A-4529-830C-700C8CE5DF28

Q24649685-9AE59EB3-C7DA-4925-A92B-05339B0899FE

Q24649685-F8443DDF-BAAE-413D-99B2-FB63C10CE672

P2860

Q24649685-199F107D-72A0-4540-B186-D6058C10F11C

Q24649685-29A3C108-4E80-49EE-A937-778A811BA445

Q24649685-46FB8C31-73BB-4188-A00A-636CDAEFADFE

Q24649685-797B17AE-5ADA-4419-9820-B2ADFF5E02BA

Q24649685-887E9A03-4F6A-47FF-B840-183EBF64F37B

Q24649685-969D2BAD-C622-41EF-B845-4ABA0323BEB0

Q24649685-AF7B5EC0-8F0F-498A-8360-DC4284F5D1D4

Q24649685-C2051ADC-B6B6-4D68-B628-0A1BB548D4FD

Q24649685-DB2B7BD5-20DB-4B65-8E2A-B2610E7A33C3

Q24649685-E362D185-E019-4457-BC1C-710BC43C52CA

P304

Q24649685-0DABF920-AA96-4C30-B4D6-55ED2FDFF5BA

P31

Q24649685-8A409B1D-372E-4EE9-A7F6-46EE702D975B

P3181

Q24649685-6D5E3608-8C58-4121-8B52-BBB65AD892C3

P356

Q24649685-73802FB3-4E12-4714-A031-8907D70D76AB

P407

Q24649685-284AFC14-FBB5-40C6-A36A-60D77F74FB60

P433

Q24649685-6C7A9729-C641-4CF4-8D6F-10101F64AD00

P478

Q24649685-2B7A8E11-F6F5-45F5-872C-41FA91893264

P577

Q24649685-9EC57E52-BAD3-4EC5-874F-7B23F955EC85

P698

Q24649685-8F6F2E77-8526-43FA-864B-A145E1CE84F2

P932

Q24649685-05DFAA29-09B1-4A75-8F47-D8E3E856A7C0

P3181

P356

P1433

Journal of the American Society of Nephrology

P1476

Supramaximal dose of candesartan in proteinuric renal disease

@en

P2093

Anthony Chiu

http://www.w3.org/2001/XMLSchema#string

Ellen Burgess

http://www.w3.org/2001/XMLSchema#string

Norman Muirhead

http://www.w3.org/2001/XMLSchema#string

Paul Rene de Cotret

http://www.w3.org/2001/XMLSchema#string

Sheldon Tobe

http://www.w3.org/2001/XMLSchema#string

Vincent Pichette

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

CKD progression and mortality among older patients with diabetes.

Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.

P304

893-900

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3595567

http://www.w3.org/2001/XMLSchema#string

P356

10.1681/ASN.2008040416

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19211712

http://www.w3.org/2001/XMLSchema#string

P932

2663827

http://www.w3.org/2001/XMLSchema#string